News
NNVC
1.160
-1.69%
-0.020
Weekly Report: what happened at NNVC last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at NNVC last week (0401-0405)?
Weekly Report · 04/08 12:15
Weekly Report: what happened at NNVC last week (0325-0329)?
Weekly Report · 04/01 12:11
Weekly Report: what happened at NNVC last week (0318-0322)?
Weekly Report · 03/25 12:15
Weekly Report: what happened at NNVC last week (0311-0315)?
Weekly Report · 03/18 12:13
Weekly Report: what happened at NNVC last week (0304-0308)?
Weekly Report · 03/11 12:08
Weekly Report: what happened at NNVC last week (0226-0301)?
Weekly Report · 03/04 12:12
Weekly Report: what happened at NNVC last week (0219-0223)?
Weekly Report · 02/26 12:31
Weekly Report: what happened at NNVC last week (0212-0216)?
Weekly Report · 02/19 12:34
NanoViricides Restructures Agreements to Alleviate Financial Stress
TipRanks · 02/16 22:03
NanoViricides Price Target Maintained With a $6.50/Share by EF Hutton
Dow Jones · 02/16 12:24
EF Hutton Reiterates Buy on Nanoviricides, Maintains $6.5 Price Target
Benzinga · 02/16 12:14
Nanoviricides Q2 EPS $(0.18) Down From $(0.15) YoY; As Of December 31, 2023, We Had Cash And Cash Equivalent Current Assets Balance Of Approximately $5.31M. Additional Agreements Have Resulted In A Further Approximately $2.5M Available Cash
Benzinga · 02/15 11:44
NanoViricides GAAP EPS of -$0.18
Seeking Alpha · 02/15 11:38
Weekly Report: what happened at NNVC last week (0205-0209)?
Weekly Report · 02/12 12:19
Weekly Report: what happened at NNVC last week (0129-0202)?
Weekly Report · 02/05 12:32
NanoViricides reports positive safety results for COVID drug candidate
Healthcare NanoViricides reports positive safety results for COVID drug candidate. The company is testing the antiviral product as a treatment for several respiratory viruses. No adverse events in any of the ascending dose cohorts for NV-CoV-2 in a Phase 1 study.
Seeking Alpha · 01/29 17:52
Weekly Report: what happened at NNVC last week (0122-0126)?
Weekly Report · 01/29 12:14
Weekly Report: what happened at NNVC last week (0115-0119)?
Weekly Report · 01/22 12:20
Nanoviricides: Current report
Press release · 01/20 00:03
More
Webull provides a variety of real-time NNVC stock news. You can receive the latest news about Nanoviricides through multiple platforms. This information may help you make smarter investment decisions.
About NNVC
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.